Clinical Trial Update: Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study [Phase 3]

View source ↗

Summary

Phase 3 non-inferiority trial evaluating maintenance pembrolizumab at standard versus low dose in metastatic non-small cell lung cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Metastatic Non-squamous Lung Cancer | Phase 3 | Status: RECRUITING